INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1255, 23629, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1256, 23630, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1257, 23631, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1258, 23635, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c3d90eb6d043108845ba180d335910622a502d6b06b24afb10c5ec5577df09e2e3f79cc37035f385cb402568254d4184eade2daa51eb06b07e28b8bb693ab83ee906753e76a4b230648971813d0b80549914ea962def1c686c23307158f00d813e047cfa886e7b0706183ce49cfc013e0a5420b832569d60252a1056729d71acbb5a6179a929418acd5ea1299b8dfa12e06eae3583edf1fa1651d8560e3ffb0ae6f2be8623763eba37999b0773d01c1c46f765c1faee3dcd6ed4da3fdf95410aabaec735d271d5a9e2649307e721f3c817f2353044891485e2fa96cf68022478e3112d3bb61b3266dfc08aff888399ad82ac031e599b093e0f30fc2489eac', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1259, 23637, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1260, 23639, 'Nitroglycerin', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1262, 4278, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1263, 4279, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1264, 13459, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1265, 23577, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1266, 23578, 'Nifedipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c3d90eb6d043108845ba180d335910622a502d6b06b24afb10c5ec5577df09e2e3f79cc37035f385cb402568254d4184eade2daa51eb06b07e28b8bb693ab83ee906753e76a4b230648971813d0b80549914ea962def1c686c23307158f00d813e047cfa886e7b0706183ce49cfc013e0a5420b832569d60252a1056729d71acbb5a6179a929418acd5ea1299b8dfa12e06eae3583edf1fa1651d8560e3ffb0ae6f2be8623763eba37999b0773d01c1c46f765c1faee3dcd6ed4da3fdf95410aabaec735d271d5a9e2649307e721f3c817f2353044891485e2fa96cf68022478e3112d3bb61b3266dfc08aff888399ad82ac031e599b093e0f30fc2489eac', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1267, 4278, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1268, 4279, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'789c7591414e03310c45afe22548d5acb8040b24165cc04d9c1943c68eeca4d5dc1e0710952ad825b6e3fffecfdb46b0a38c82a90f2373d002c28532371602941c57d7fa73374abaef1455bc2867961556c346c50677781f9c680178c5ce24dda11b61a70c6a58eb0157ee1b68dfc820614d3c76481b8a508573d5f431f57dd351339c433b5fd8e371d76f31482a3ef6d659656256b435a6761d532a0a3712ff02bf279b9b9ad125d0a27fc0903c084a1de11de756071670b2e0ca3656a8315b3d0c3d4b0a2713864aa134e564226b9e0bdd23ba88f180160ed83b1435186dea3d41c623704a0fd3e1fcdec41fe9bda870579bd9ce3dff2435e30935fa257aa0655d4eb011664c1bc5e968da493c944ee087246d51edd13c125a663c0165daf111d86f1f4b79f904ebe9c547', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1269, 13459, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1270, 23577, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c5d92c16edc300c447f85c704688202493f20d943af3d24871e6989b6984aa2404a59f8ef4b39c906d89b658b336f867e490441aa8dd23a4b055961536cb4eae00e6f830341c11d16023493c0d829c2997b02e3adf2ca016bcf3b700d4a68feb165b482533550ed8a53d7a6b0497133cc81478190b056cab06409ff480d6e4ea767bb8573a20a3dd10ea8ee190b57b64eeac2a298f37e0ff0e2d04da5c9b42b34a5d80ab03945e285bf929cfefe79fcf5131e9e1eef0ac50ff495d5fa5df3303ed971917c8c1e9eb08d0e673781658740dad1df07294d468de696649e685efeeee81387ab3362389c139af7e531949ae8a5af691039edd1c977e5c8956066861b1754195bf21a231d3572dd3c6e249d310a7ad17d44ba8595b2446e3efa033cb3e4efc34a5fcf58a39fcbe5a2acdd610e0684c45b72974d89a6f6c1cd35f23bc78119de511917cedc67d1bfaf7f8580e3e85c7c37dd6b877e96d5292eeb9f2bb8a2bc06bb50c3d3ebc9eeff03b75cebb9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1271, 23578, 'Nifedipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  The interaction has been reported with the dihydropyridine CCBs (in roughly decreasing order of magnitude) felodipine, nisoldipine, nifedipine, and nimodipine, often with a high degree of interindividual variability.  Grapefruit juice caused more than twofold increases in felodipine, nifedipine, and nisoldipine AUCs.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'789c7591414e03310c45afe22548d5acb8040b24165cc04d9c1943c68eeca4d5dc1e0710952ad825b6e3fffecfdb46b0a38c82a90f2373d002c28532371602941c57d7fa73374abaef1455bc2867961556c346c50677781f9c680178c5ce24dda11b61a70c6a58eb0157ee1b68dfc820614d3c76481b8a508573d5f431f57dd351339c433b5fd8e371d76f31482a3ef6d659656256b435a6761d532a0a3712ff02bf279b9b9ad125d0a27fc0903c084a1de11de756071670b2e0ca3656a8315b3d0c3d4b0a2713864aa134e564226b9e0bdd23ba88f180160ed83b1435186dea3d41c623704a0fd3e1fcdec41fe9bda870579bd9ce3dff2435e30935fa257aa0655d4eb011664c1bc5e968da493c944ee087246d51edd13c125a663c0165daf111d86f1f4b79f904ebe9c547', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1273, 23613, 'Nitroprusside', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1274, 23627, 'Nitroprusside', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1276, 4285, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1277, 8666, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1278, 8969, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1279, 8970, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1280, 9312, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1281, 23701, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1282, 23722, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'orange juice', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1283, 4285, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1284, 8666, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1285, 8969, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1286, 8970, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1287, 9312, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'789c45914d56c3300c84af324bfa5e9a4bb062c7820b28b69208142bf827afbe3d4aa165edd1cc37e3574ba1e5cca942d2c2a58a25d88c8d49cb8048923bf66cb1855af0b2897e0de8b6b45c2fb08c401aa46dd7d97295593862368bae9491c70181b31b0dae2477c76793c0176cd41139f85361d4954153b1bc3fb25dac489667b51b054923f0e1a28dc34a49ca0629082b2b3d0efe204029deedbe9b24534b3c2073695abd9ad77b66464c627490284da252bb27bca5fb6938917e199ec083dfae32c9234e523d874a4e595d5676effe4fe7dddfaf8bf6603e5b658ff5992c2ffe189cd03daecfab936b37ed3b7bf9c8e582a963563a9cbddc67f25f304cec9987e9c171fc01c4fb9f1a');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1288, 23701, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1289, 23722, 'Norfloxacin', 'Concurrent ingestion of meals, dairy products (milk, yogurt) or calcium-fortified foods (i.e., cereal, orange juice) may decrease the absorption of oral norfloxacin.  The mechanism is chelation of calcium and the quinolone, resulting in decreased bioavailability.  In the case of orange juice, inhibition of intestinal transport mechanisms (P-glycoprotein or organic anion-transporting polypeptides) by flavones may also be involved.', 'dairy products', 'Moderate', '', 'DDInter', 0, X'789c1dccd10dc2300c84e1556e80c22acc601247b5eae490e30ad89e94d7ef3fdd23c43118cdf991620373e7e9154f45caa10392709599e050ac162b358682817cf34f13d2520382aee21bbaf9b15d03e6beb88ac517af603d4bcecb8b78b1b3dfd6515a33ad68649df71f7bac33e0', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1291, 2569, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', '', 'DDInter', 0, X'789c0dc8d10d80200c04d0556e02977012a88d5c82570325acafeff39da1c9cb072c96a677eac68ec785526325b271824a1fc59221ec466bf873e91d7ed1b2d4eec707f2c61b87', NULL, X'789c358ed18dc3300c4357e10045a7e9028acdd4c2d956602901d2e9cfbe43ff0881e27baf4224f61852d1392e3b1d7e7bb081fbce140ee9195b35cba8bc581db68351a45b45931b1ba13d0d8a33cf844342e7a223e447fb1bb6b6932d46e2117ad11f901ac5ce77419610c820aaa4bffac20d1e36167adeff3fb3a6b0713f81d7346e4c93afdebe02f924c2c0feb9dbd229ba69a8f5e72f961152d9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1292, 8983, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', '', 'DDInter', 0, X'789c0dc8d10d80200c04d0556e02977012a88d5c82570325acafeff39da1c9cb072c96a677eac68ec785526325b271824a1fc59221ec466bf873e91d7ed1b2d4eec707f2c61b87', NULL, X'789c358ed18dc3300c4357e10045a7e9028acdd4c2d956602901d2e9cfbe43ff0881e27baf4224f61852d1392e3b1d7e7bb081fbce140ee9195b35cba8bc581db68351a45b45931b1ba13d0d8a33cf844342e7a223e447fb1bb6b6932d46e2117ad11f901ac5ce77419610c820aaa4bffac20d1e36167adeff3fb3a6b0713f81d7346e4c93afdebe02f924c2c0feb9dbd229ba69a8f5e72f961152d9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1293, 16315, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', '', 'DDInter', 0, X'789c0dc8d10d80200c04d0556e02977012a88d5c82570325acafeff39da1c9cb072c96a677eac68ec785526325b271824a1fc59221ec466bf873e91d7ed1b2d4eec707f2c61b87', NULL, X'789c358ed18dc3300c4357e10045a7e9028acdd4c2d956602901d2e9cfbe43ff0881e27baf4224f61852d1392e3b1d7e7bb081fbce140ee9195b35cba8bc581db68351a45b45931b1ba13d0d8a33cf844342e7a223e447fb1bb6b6932d46e2117ad11f901ac5ce77419610c820aaa4bffac20d1e36167adeff3fb3a6b0713f81d7346e4c93afdebe02f924c2c0feb9dbd229ba69a8f5e72f961152d9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1294, 25248, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', '', 'DDInter', 0, X'789c0dc8d10d80200c04d0556e02977012a88d5c82570325acafeff39da1c9cb072c96a677eac68ec785526325b271824a1fc59221ec466bf873e91d7ed1b2d4eec707f2c61b87', NULL, X'789c358ed18dc3300c4357e10045a7e9028acdd4c2d956602901d2e9cfbe43ff0881e27baf4224f61852d1392e3b1d7e7bb081fbce140ee9195b35cba8bc581db68351a45b45931b1ba13d0d8a33cf844342e7a223e447fb1bb6b6932d46e2117ad11f901ac5ce77419610c820aaa4bffac20d1e36167adeff3fb3a6b0713f81d7346e4c93afdebe02f924c2c0feb9dbd229ba69a8f5e72f961152d9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1295, 27513, 'Norethisterone', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', '', 'DDInter', 0, X'789c0dc8d10d80200c04d0556e02977012a88d5c82570325acafeff39da1c9cb072c96a677eac68ec785526325b271824a1fc59221ec466bf873e91d7ed1b2d4eec707f2c61b87', NULL, X'789c358ed18dc3300c4357e10045a7e9028acdd4c2d956602901d2e9cfbe43ff0881e27baf4224f61852d1392e3b1d7e7bb081fbce140ee9195b35cba8bc581db68351a45b45931b1ba13d0d8a33cf844342e7a223e447fb1bb6b6932d46e2117ad11f901ac5ce77419610c820aaa4bffac20d1e36167adeff3fb3a6b0713f81d7346e4c93afdebe02f924c2c0feb9dbd229ba69a8f5e72f961152d9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1296, 2569, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'789c7d8f4b4e04310c44af52271821311c00b160c96c59ba13276d944f2b7666e8dbe30604ac585a65fbbdba90093753dcd68ec179161a6547e84d6765e4411ba731c5d0c7dfe96d4a60e8da67895818b537b13e3822f922c52b0f65704a1cfc39b5082ac647be15d24a0721387838df59e80971ccacb0950cb3451eb94325374912a819b6c1baab719580ca464b2fa215cb8ea7d7cbf9e10ef78fe713f0fceb7850ff51a66b97e842927c13d25c8fc2610351e8d4cdd539facb97412df3f7bd67ad1bf8fd2b86f59f53dcc4562fc0defcb3cce903c9bb8157', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1297, 8983, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'789c7d8f4b4e04310c44af52271821311c00b160c96c59ba13276d944f2b7666e8dbe30604ac585a65fbbdba90093753dcd68ec179161a6547e84d6765e4411ba731c5d0c7dfe96d4a60e8da67895818b537b13e3822f922c52b0f65704a1cfc39b5082ac647be15d24a0721387838df59e80971ccacb0950cb3451eb94325374912a819b6c1baab719580ca464b2fa215cb8ea7d7cbf9e10ef78fe713f0fceb7850ff51a66b97e842927c13d25c8fc2610351e8d4cdd539facb97412df3f7bd67ad1bf8fd2b86f59f53dcc4562fc0defcb3cce903c9bb8157', NULL, X'789c6d54c96edb3010fd953926806d1468fa016d0e456f39e4d2e3881a5193721148caaefaf57d230b8d5ce7a66de6add4f7c2930c65d6466fb33aa1c80b697245b80ab551680a5c2393cbc9496a859be654290f940b87b010f75193d626457aeacbec2bc6b81117a13a77d546641db06dcf3f5f9ebe7ca2cf5f9f486b96f4678972227a35a092a75cb1248a1b192b233e0197513b35505bf13e7e8cd22b36f73468a9ed3871ad986cdce5b08ea615cfcf8d2ee049dd424e4a633c77394e794e7d05a45488b28ffd3f2340e79b389ea1dfffefcec6c6263572d16066415ed3c481a0749462f2138d32c12ab7637c580945f649dbdc8bc9b1d9c26e5507ad1eaedb321ab26d81197b43c1588acf54151b06750ce2266081f711483bf110bb33fa414f723a6cab2eda460af9b2c6479d663eb306ee34685b1ea1fd07bc90045ae14a5886415c33b6f76ed4db5a1c0102d247e2d41bb589b7e7bd4c02f6a91dd657a04e672e0bc8f462158a3979ea0ade553078de72da6da81fe23fc8c943d8a87e5c810d7eee027ad78a24dfc6471af98cdb0c6f34a285bd00ea5a4930cced1afec70d3bd065542ccb6ba837643660b3f18a5b35f97bdcb64c88c90ec90d6ecc0812573b64a87e19b94476f99726b1e2ecba61a7e09cc31920f726d839e350b31db6374baa65e2cd1341a3de8b668534c1b05eb7c02de2b95e73febdba8169c8762376783d0b52d8a6ecc7d0016aad035420fc5e07f4700eeb140cead5b5d35f2262912e');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1298, 16315, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'789c7d8f4b4e04310c44af52271821311c00b160c96c59ba13276d944f2b7666e8dbe30604ac585a65fbbdba90093753dcd68ec179161a6547e84d6765e4411ba731c5d0c7dfe96d4a60e8da67895818b537b13e3822f922c52b0f65704a1cfc39b5082ac647be15d24a0721387838df59e80971ccacb0950cb3451eb94325374912a819b6c1baab719580ca464b2fa215cb8ea7d7cbf9e10ef78fe713f0fceb7850ff51a66b97e842927c13d25c8fc2610351e8d4cdd539facb97412df3f7bd67ad1bf8fd2b86f59f53dcc4562fc0defcb3cce903c9bb8157', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1299, 25248, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'789c7d8f4b4e04310c44af52271821311c00b160c96c59ba13276d944f2b7666e8dbe30604ac585a65fbbdba90093753dcd68ec179161a6547e84d6765e4411ba731c5d0c7dfe96d4a60e8da67895818b537b13e3822f922c52b0f65704a1cfc39b5082ac647be15d24a0721387838df59e80971ccacb0950cb3451eb94325374912a819b6c1baab719580ca464b2fa215cb8ea7d7cbf9e10ef78fe713f0fceb7850ff51a66b97e842927c13d25c8fc2610351e8d4cdd539facb97412df3f7bd67ad1bf8fd2b86f59f53dcc4562fc0defcb3cce903c9bb8157', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1300, 27513, 'Norethisterone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'789c7d8f4b4e04310c44af52271821311c00b160c96c59ba13276d944f2b7666e8dbe30604ac585a65fbbdba90093753dcd68ec179161a6547e84d6765e4411ba731c5d0c7dfe96d4a60e8da67895818b537b13e3822f922c52b0f65704a1cfc39b5082ac647be15d24a0721387838df59e80971ccacb0950cb3451eb94325374912a819b6c1baab719580ca464b2fa215cb8ea7d7cbf9e10ef78fe713f0fceb7850ff51a66b97e842927c13d25c8fc2610351e8d4cdd539facb97412df3f7bd67ad1bf8fd2b86f59f53dcc4562fc0defcb3cce903c9bb8157', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1301, 10188, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', '', 'DDInter', 0, X'789c4d8fd171033108445bd9023c2e22a9044bf88e8c043780ecb8fb70f64f7e99c7eebeef212a4d4803b1db1a1d37063dc9197647ee8cc392358506eee6a091ecdc41b7303f524c4fae99369b92a4395ea03e2b343ea0797d4eeed2e8a4037db9e88674a69c958ca7e48eb049699105294869d81657e06b98750c7ef0883a77b4f7de8a748ea3e2f8dfec692a69557ac1419ed2d620af3de7eeee6b8bf2a1c44e8f528492bb3d4f45a78357e110edfc7b79f79ce6dd8236aedefeb3caa6a403ca8d23c85fd73fdb3b75da', NULL, X'789c6d90416ec5300844af32cb568a728adea02720368991628880fc2ab7aff3d5c5afda1d42c3cc1b3e4e461ab2b138368a74134d8e14a51d4723ef546cb74d0a785db9644c08eb94164943051a42db026f3c6ff3042be96c299527eca43ff33b3a5d78908b9db15fa0a7d51d0b5ac2fc483185ada8c2497e41cf7461cd18fe15c5b4589724cdfbb876518964e70af3c1d9b94aa1db2366e0f33fbc460fc6c2ac88665f7a973e7c14d3ed6fed74d29081279d9ff9a24d96b178d1fcc61e1fe117e6384b030556caf91b8c5785a8');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1302, 12372, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', '', 'DDInter', 0, X'789c4d8fd171033108445bd9023c2e22a9044bf88e8c043780ecb8fb70f64f7e99c7eebeef212a4d4803b1db1a1d37063dc9197647ee8cc392358506eee6a091ecdc41b7303f524c4fae99369b92a4395ea03e2b343ea0797d4eeed2e8a4037db9e88674a69c958ca7e48eb049699105294869d81657e06b98750c7ef0883a77b4f7de8a748ea3e2f8dfec692a69557ac1419ed2d620af3de7eeee6b8bf2a1c44e8f528492bb3d4f45a78357e110edfc7b79f79ce6dd8236aedefeb3caa6a403ca8d23c85fd73fdb3b75da', NULL, X'789c6d90416ec5300844af32cb568a728adea02720368991628880fc2ab7aff3d5c5afda1d42c3cc1b3e4e461ab2b138368a74134d8e14a51d4723ef546cb74d0a785db9644c08eb94164943051a42db026f3c6ff3042be96c299527eca43ff33b3a5d78908b9db15fa0a7d51d0b5ac2fc483185ada8c2497e41cf7461cd18fe15c5b4589724cdfbb876518964e70af3c1d9b94aa1db2366e0f33fbc460fc6c2ac88665f7a973e7c14d3ed6fed74d29081279d9ff9a24d96b178d1fcc61e1fe117e6384b030556caf91b8c5785a8');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1303, 15062, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', '', 'DDInter', 0, X'789c4d8fd171033108445bd9023c2e22a9044bf88e8c043780ecb8fb70f64f7e99c7eebeef212a4d4803b1db1a1d37063dc9197647ee8cc392358506eee6a091ecdc41b7303f524c4fae99369b92a4395ea03e2b343ea0797d4eeed2e8a4037db9e88674a69c958ca7e48eb049699105294869d81657e06b98750c7ef0883a77b4f7de8a748ea3e2f8dfec692a69557ac1419ed2d620af3de7eeee6b8bf2a1c44e8f528492bb3d4f45a78357e110edfc7b79f79ce6dd8236aedefeb3caa6a403ca8d23c85fd73fdb3b75da', NULL, X'789c6d90416ec5300844af32cb568a728adea02720368991628880fc2ab7aff3d5c5afda1d42c3cc1b3e4e461ab2b138368a74134d8e14a51d4723ef546cb74d0a785db9644c08eb94164943051a42db026f3c6ff3042be96c299527eca43ff33b3a5d78908b9db15fa0a7d51d0b5ac2fc483185ada8c2497e41cf7461cd18fe15c5b4589724cdfbb876518964e70af3c1d9b94aa1db2366e0f33fbc460fc6c2ac88665f7a973e7c14d3ed6fed74d29081279d9ff9a24d96b178d1fcc61e1fe117e6384b030556caf91b8c5785a8');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1304, 15063, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', '', 'DDInter', 0, X'789c4d8fd171033108445bd9023c2e22a9044bf88e8c043780ecb8fb70f64f7e99c7eebeef212a4d4803b1db1a1d37063dc9197647ee8cc392358506eee6a091ecdc41b7303f524c4fae99369b92a4395ea03e2b343ea0797d4eeed2e8a4037db9e88674a69c958ca7e48eb049699105294869d81657e06b98750c7ef0883a77b4f7de8a748ea3e2f8dfec692a69557ac1419ed2d620af3de7eeee6b8bf2a1c44e8f528492bb3d4f45a78357e110edfc7b79f79ce6dd8236aedefeb3caa6a403ca8d23c85fd73fdb3b75da', NULL, X'789c6d90416ec5300844af32cb568a728adea02720368991628880fc2ab7aff3d5c5afda1d42c3cc1b3e4e461ab2b138368a74134d8e14a51d4723ef546cb74d0a785db9644c08eb94164943051a42db026f3c6ff3042be96c299527eca43ff33b3a5d78908b9db15fa0a7d51d0b5ac2fc483185ada8c2497e41cf7461cd18fe15c5b4589724cdfbb876518964e70af3c1d9b94aa1db2366e0f33fbc460fc6c2ac88665f7a973e7c14d3ed6fed74d29081279d9ff9a24d96b178d1fcc61e1fe117e6384b030556caf91b8c5785a8');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1305, 26499, 'Octreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', '', 'DDInter', 0, X'789c4d8fd171033108445bd9023c2e22a9044bf88e8c043780ecb8fb70f64f7e99c7eebeef212a4d4803b1db1a1d37063dc9197647ee8cc392358506eee6a091ecdc41b7303f524c4fae99369b92a4395ea03e2b343ea0797d4eeed2e8a4037db9e88674a69c958ca7e48eb049699105294869d81657e06b98750c7ef0883a77b4f7de8a748ea3e2f8dfec692a69557ac1419ed2d620af3de7eeee6b8bf2a1c44e8f528492bb3d4f45a78357e110edfc7b79f79ce6dd8236aedefeb3caa6a403ca8d23c85fd73fdb3b75da', NULL, X'789c6d90416ec5300844af32cb568a728adea02720368991628880fc2ab7aff3d5c5afda1d42c3cc1b3e4e461ab2b138368a74134d8e14a51d4723ef546cb74d0a785db9644c08eb94164943051a42db026f3c6ff3042be96c299527eca43ff33b3a5d78908b9db15fa0a7d51d0b5ac2fc483185ada8c2497e41cf7461cd18fe15c5b4589724cdfbb876518964e70af3c1d9b94aa1db2366e0f33fbc460fc6c2ac88665f7a973e7c14d3ed6fed74d29081279d9ff9a24d96b178d1fcc61e1fe117e6384b030556caf91b8c5785a8');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1306, 2736, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d505d4e04210cbe4a0fa07b07e3bb31f1045da6b334423b9632eb787a0babab0f2450be7e7fafe84ce20d8c12f1ce7281e797b7474cce3b015ee65fcbdacb0267822b9ad002ba82676ec0e26403ab02280be0b2738b7f57c05d398006852b3b2495d6eb3691b18d2569d6720278aae75ed0d50ed87ebdfce925edd2a8fca7ccf885b6686f304d72ec0cf71f9d6db84f5ab7424e50830a4b2891b9506bd360d5500a8cdac282d34d17e71271e88077d12be438f16af7f4b8ae947ccceac324092ba2ceeb31666cb0e5a3716214e0f546449f1b59644914d714e2a3cc10de4c8bca25e244c94093b8c50afaadca952c3a66cf3fcca25647867bd0d337690fa19b', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1307, 2985, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1308, 9201, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1309, 9202, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1310, 9270, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1311, 16732, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1312, 16733, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1313, 24031, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1314, 24032, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1315, 24033, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1316, 24137, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1317, 24606, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1318, 24607, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1319, 31082, 'Olopatadine (nasal)', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c1d8ecb0dc3300c4357e100fdcc50f4de4bd101545b49d4d896612901b27deddc04f03d528f1474d1844c07aa3a171772866966e8045f1875a1962968d25902789a38b88df0f97a5f29b8ec0c9abb6937e0630c29089abf52c845cb59ddd8b6e423a118e55442371a25146ebb6e063bcc392372edb00d914abc6b83e44ad272c7c7e86f8bf3b82ffd3729ab94f93240543bc2a259bd1bb64a4a76fb0301fd51b0');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1320, 741, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c3d90eb6d043108845ba180d335910622a502d6b06b24afb10c5ec5577df09e2e3f79cc37035f385cb402568254d4184eade2daa51eb06b07e28b8bb693ab83ee906753e76a4b230648971813d0b80549914ea962def1c686c23307158f00d813e047cfa886e7b0706183ce49cfc013e0a5420b832569d60252a1056729d71acbb5a6179a929418acd5ea1299b8dfa12e06eae3583edf1fa1651d8560e3ffb0ae6f2be8623763eba37999b0773d01c1c46f765c1faee3dcd6ed4da3fdf95410aabaec735d271d5a9e2649307e721f3c817f2353044891485e2fa96cf68022478e3112d3bb61b3266dfc08aff888399ad82ac031e599b093e0f30fc2489eac', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1321, 744, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1322, 4331, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1323, 14174, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1324, 18498, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1325, 18500, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c3d90eb6d043108845ba180d335910622a502d6b06b24afb10c5ec5577df09e2e3f79cc37035f385cb402568254d4184eade2daa51eb06b07e28b8bb693ab83ee906753e76a4b230648971813d0b80549914ea962def1c686c23307158f00d813e047cfa886e7b0706183ce49cfc013e0a5420b832569d60252a1056729d71acbb5a6179a929418acd5ea1299b8dfa12e06eae3583edf1fa1651d8560e3ffb0ae6f2be8623763eba37999b0773d01c1c46f765c1faee3dcd6ed4da3fdf95410aabaec735d271d5a9e2649307e721f3c817f2353044891485e2fa96cf68022478e3112d3bb61b3266dfc08aff888399ad82ac031e599b093e0f30fc2489eac', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1326, 21783, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1327, 21784, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1328, 23726, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1329, 23727, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1330, 24018, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1331, 24019, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c55504b72c33008bd0acb76c6f125b26e373d019148c454161a81d3e8f645b217ed8e81f7789f0f2c1daaf690c41235acb41b07c012e1faf975c160fc24c007155378a3f5b12e7e7cb1e4ee385d4029e2c0f8987a2d726cb11847aa8d547d3c17a7cc044865e1380e394892bcc0b66bc8048d32be06e71de895f8c636fe8a51d1e184ee770ae32169a5c0987387b8372e0fe0c2c6ee450ac81d8e347d2689a2ced480799e5780ab60dc9ca0d60ec60f5b9a265d8cdaa9a6933d8bf967e2a8637145a8d83cd09eb1c1135522bb84b48388b926bcdcb2846f6a0edfb07b3cddb30d26c6c8f62712b80bc74a8459dbdee8506f96440d9575fd05d6c1a145');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1332, 24021, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c3d90eb6d043108845ba180d335910622a502d6b06b24afb10c5ec5577df09e2e3f79cc37035f385cb402568254d4184eade2daa51eb06b07e28b8bb693ab83ee906753e76a4b230648971813d0b80549914ea962def1c686c23307158f00d813e047cfa886e7b0706183ce49cfc013e0a5420b832569d60252a1056729d71acbb5a6179a929418acd5ea1299b8dfa12e06eae3583edf1fa1651d8560e3ffb0ae6f2be8623763eba37999b0773d01c1c46f765c1faee3dcd6ed4da3fdf95410aabaec735d271d5a9e2649307e721f3c817f2353044891485e2fa96cf68022478e3112d3bb61b3266dfc08aff888399ad82ac031e599b093e0f30fc2489eac', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1333, 24022, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1334, 24023, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1335, 29054, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1336, 31021, 'Olmesartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c3d90eb6d043108845ba180d335910622a502d6b06b24afb10c5ec5577df09e2e3f79cc37035f385cb402568254d4184eade2daa51eb06b07e28b8bb693ab83ee906753e76a4b230648971813d0b80549914ea962def1c686c23307158f00d813e047cfa886e7b0706183ce49cfc013e0a5420b832569d60252a1056729d71acbb5a6179a929418acd5ea1299b8dfa12e06eae3583edf1fa1651d8560e3ffb0ae6f2be8623763eba37999b0773d01c1c46f765c1faee3dcd6ed4da3fdf95410aabaec735d271d5a9e2649307e721f3c817f2353044891485e2fa96cf68022478e3112d3bb61b3266dfc08aff888399ad82ac031e599b093e0f30fc2489eac', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1337, 741, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'789c6591516ec3300c43afa203a4bdc7fe7a05d5661a218e155872b6dc7e72b7a140f76b50e4237d63175437b2457bc9d4902007280b9cdb49497b3514a90fe29ae90ee27c8821932b5575ea06dad5d94cfa76495a9da50eb97171b27e3717ef0e236da407dac5175c86ada3bd2e43b9ef05db93e5533c683cc2abf5e2c32d8e24e4cb699284eb95e863fe1fc10d03288fcbd45b0bb7724e51ead10b37dab48a6b1b7e1ad76891fb222838508cc4c608ba054a468ea0dbdb445c4cdf863060a50d59121762f7908b569279709f84af1d2d3c12c8ce6d77dd6c002c673caf1cad85a3465a88a33b78ad309b48da1ff7026e7e07fb348acdddc27ca2b14bf9ed123191e22dac02368e63ec19cf7ffb89021f326c49ea535cf0b0eb3796edbfbf', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1338, 744, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'789c6591516ec3300c43afa203a4bdc7fe7a05d5661a218e155872b6dc7e72b7a140f76b50e4237d63175437b2457bc9d4902007280b9cdb49497b3514a90fe29ae90ee27c8821932b5575ea06dad5d94cfa76495a9da50eb97171b27e3717ef0e236da407dac5175c86ada3bd2e43b9ef05db93e5533c683cc2abf5e2c32d8e24e4cb699284eb95e863fe1fc10d03288fcbd45b0bb7724e51ead10b37dab48a6b1b7e1ad76891fb222838508cc4c608ba054a468ea0dbdb445c4cdf863060a50d59121762f7908b569279709f84af1d2d3c12c8ce6d77dd6c002c673caf1cad85a3465a88a33b78ad309b48da1ff7026e7e07fb348acdddc27ca2b14bf9ed123191e22dac02368e63ec19cf7ffb89021f326c49ea535cf0b0eb3796edbfbf', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1339, 4331, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1340, 14174, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1341, 18498, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'789c6591516ec3300c43afa203a4bdc7fe7a05d5661a218e155872b6dc7e72b7a140f76b50e4237d63175437b2457bc9d4902007280b9cdb49497b3514a90fe29ae90ee27c8821932b5575ea06dad5d94cfa76495a9da50eb97171b27e3717ef0e236da407dac5175c86ada3bd2e43b9ef05db93e5533c683cc2abf5e2c32d8e24e4cb699284eb95e863fe1fc10d03288fcbd45b0bb7724e51ead10b37dab48a6b1b7e1ad76891fb222838508cc4c608ba054a468ea0dbdb445c4cdf863060a50d59121762f7908b569279709f84af1d2d3c12c8ce6d77dd6c002c673caf1cad85a3465a88a33b78ad309b48da1ff7026e7e07fb348acdddc27ca2b14bf9ed123191e22dac02368e63ec19cf7ffb89021f326c49ea535cf0b0eb3796edbfbf', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1342, 18500, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1343, 21783, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1344, 21784, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'789c6591516ec3300c43afa203a4bdc7fe7a05d5661a218e155872b6dc7e72b7a140f76b50e4237d63175437b2457bc9d4902007280b9cdb49497b3514a90fe29ae90ee27c8821932b5575ea06dad5d94cfa76495a9da50eb97171b27e3717ef0e236da407dac5175c86ada3bd2e43b9ef05db93e5533c683cc2abf5e2c32d8e24e4cb699284eb95e863fe1fc10d03288fcbd45b0bb7724e51ead10b37dab48a6b1b7e1ad76891fb222838508cc4c608ba054a468ea0dbdb445c4cdf863060a50d59121762f7908b569279709f84af1d2d3c12c8ce6d77dd6c002c673caf1cad85a3465a88a33b78ad309b48da1ff7026e7e07fb348acdddc27ca2b14bf9ed123191e22dac02368e63ec19cf7ffb89021f326c49ea535cf0b0eb3796edbfbf', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1345, 23726, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1346, 23727, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'789c6591516ec3300c43afa203a4bdc7fe7a05d5661a218e155872b6dc7e72b7a140f76b50e4237d63175437b2457bc9d4902007280b9cdb49497b3514a90fe29ae90ee27c8821932b5575ea06dad5d94cfa76495a9da50eb97171b27e3717ef0e236da407dac5175c86ada3bd2e43b9ef05db93e5533c683cc2abf5e2c32d8e24e4cb699284eb95e863fe1fc10d03288fcbd45b0bb7724e51ead10b37dab48a6b1b7e1ad76891fb222838508cc4c608ba054a468ea0dbdb445c4cdf863060a50d59121762f7908b569279709f84af1d2d3c12c8ce6d77dd6c002c673caf1cad85a3465a88a33b78ad309b48da1ff7026e7e07fb348acdddc27ca2b14bf9ed123191e22dac02368e63ec19cf7ffb89021f326c49ea535cf0b0eb3796edbfbf', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1347, 24018, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1348, 24019, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1349, 24021, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1350, 24022, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1351, 24023, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1352, 29054, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1353, 31021, 'Olmesartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).', 'Food High in Potassium', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c158c310ec2400c04bfb22548813f404741c30f9c64c959b99c4fb62394df03e54833f3b4992ec94bdaa5e852302b53fc80b69495b037baa544e8be0d60744e2ab51e08a989d8c748cd3d190336f957935382c842b8c6fa1f94a3d357a9dc547e06c236a24b2a5b063ec5204eeca16d81b4452dd97e80c703ce893dcd31569b567ae0747bdde37cfd02e87643e9');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1356, 1088, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1357, 1089, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1358, 1090, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1359, 1094, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1360, 1095, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1361, 1097, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1362, 1678, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1363, 4008, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1364, 4009, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1365, 4735, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1366, 7349, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1367, 7350, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1368, 7352, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1369, 7355, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1370, 7359, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1371, 7372, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1372, 7397, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1373, 7398, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1374, 7399, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1375, 11556, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1376, 13234, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1377, 13512, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'789c8d524172c33008fc0a0f68d33774fa811efa0162e38846162e4849fdfb821c4f3239f586a4655976f5216590992b960acd086402ab58b9c04c230f5e49812bd704d68e1630c60c3f2d8aca64d18079902419665c81cba0844e541381b29d03906871a2c11fbf9bae07802fc5624c3e73c79b5760a46d861a8f3873e9d7092f0447a2024a8b68a5f1266753199ab1f85de2dc87faf9ce79a2428a39afde6c929d4914785e54bcec3483f822a539abf72a2e6b20108eca34395125d5b674137cd80df2d20b7a94867e5cc4ea8c7a26273cddd4767f26acee59a82c525eb7d36ec9849c9b8666880bb7c4a0e23918b60dcdedfadc5fae4942b1b599fe91874f7cf36dba4c84c45645d70064be90c2c8d6938ad88e8eb887316ec94dd1fc1cddfb50bdfb89c281add0ef92914b58f9902050a64bff4606e15218ae0edb3f97af2b0f611efe007d34f5bc');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1378, 14227, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1379, 14228, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1380, 14563, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1381, 14570, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1382, 15442, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1383, 16266, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1384, 18869, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1385, 21870, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1386, 21882, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1387, 21884, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1388, 21885, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1389, 21887, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1390, 21889, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1391, 21890, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1392, 21891, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1393, 21893, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1394, 21894, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'789c8d524172c33008fc0a0f68d33774fa811efa0162e38846162e4849fdfb821c4f3239f586a4655976f5216590992b960acd086402ab58b9c04c230f5e49812bd704d68e1630c60c3f2d8aca64d18079902419665c81cba0844e541381b29d03906871a2c11fbf9bae07802fc5624c3e73c79b5760a46d861a8f3873e9d7092f0447a2024a8b68a5f1266753199ab1f85de2dc87faf9ce79a2428a39afde6c929d4914785e54bcec3483f822a539abf72a2e6b20108eca34395125d5b674137cd80df2d20b7a94867e5cc4ea8c7a26273cddd4767f26acee59a82c525eb7d36ec9849c9b8666880bb7c4a0e23918b60dcdedfadc5fae4942b1b599fe91874f7cf36dba4c84c45645d70064be90c2c8d6938ad88e8eb887316ec94dd1fc1cddfb50bdfb89c281add0ef92914b58f9902050a64bff4606e15218ae0edb3f97af2b0f611efe007d34f5bc');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1395, 21905, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1396, 21906, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1397, 21907, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1398, 21915, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1399, 21916, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1400, 21935, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1401, 21936, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1402, 24268, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1403, 26314, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'789c8d524172c33008fc0a0f68d33774fa811efa0162e38846162e4849fdfb821c4f3239f586a4655976f5216590992b960acd086402ab58b9c04c230f5e49812bd704d68e1630c60c3f2d8aca64d18079902419665c81cba0844e541381b29d03906871a2c11fbf9bae07802fc5624c3e73c79b5760a46d861a8f3873e9d7092f0447a2024a8b68a5f1266753199ab1f85de2dc87faf9ce79a2428a39afde6c929d4914785e54bcec3483f822a539abf72a2e6b20108eca34395125d5b674137cd80df2d20b7a94867e5cc4ea8c7a26273cddd4767f26acee59a82c525eb7d36ec9849c9b8666880bb7c4a0e23918b60dcdedfadc5fae4942b1b599fe91874f7cf36dba4c84c45645d70064be90c2c8d6938ad88e8eb887316ec94dd1fc1cddfb50bdfb89c281add0ef92914b58f9902050a64bff4606e15218ae0edb3f97af2b0f611efe007d34f5bc');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1404, 26558, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1405, 26559, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'789c8d524172c33008fc0a0f68d33774fa811efa0162e38846162e4849fdfb821c4f3239f586a4655976f5216590992b960acd086402ab58b9c04c230f5e49812bd704d68e1630c60c3f2d8aca64d18079902419665c81cba0844e541381b29d03906871a2c11fbf9bae07802fc5624c3e73c79b5760a46d861a8f3873e9d7092f0447a2024a8b68a5f1266753199ab1f85de2dc87faf9ce79a2428a39afde6c929d4914785e54bcec3483f822a539abf72a2e6b20108eca34395125d5b674137cd80df2d20b7a94867e5cc4ea8c7a26273cddd4767f26acee59a82c525eb7d36ec9849c9b8666880bb7c4a0e23918b60dcdedfadc5fae4942b1b599fe91874f7cf36dba4c84c45645d70064be90c2c8d6938ad88e8eb887316ec94dd1fc1cddfb50bdfb89c281add0ef92914b58f9902050a64bff4606e15218ae0edb3f97af2b0f611efe007d34f5bc');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1406, 26940, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1407, 26941, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1408, 28349, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1409, 28350, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1410, 29588, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1411, 30215, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'789c8d524172c33008fc0a0f68d33774fa811efa0162e38846162e4849fdfb821c4f3239f586a4655976f5216590992b960acd086402ab58b9c04c230f5e49812bd704d68e1630c60c3f2d8aca64d18079902419665c81cba0844e541381b29d03906871a2c11fbf9bae07802fc5624c3e73c79b5760a46d861a8f3873e9d7092f0447a2024a8b68a5f1266753199ab1f85de2dc87faf9ce79a2428a39afde6c929d4914785e54bcec3483f822a539abf72a2e6b20108eca34395125d5b674137cd80df2d20b7a94867e5cc4ea8c7a26273cddd4767f26acee59a82c525eb7d36ec9849c9b8666880bb7c4a0e23918b60dcdedfadc5fae4942b1b599fe91874f7cf36dba4c84c45645d70064be90c2c8d6938ad88e8eb887316ec94dd1fc1cddfb50bdfb89c281add0ef92914b58f9902050a64bff4606e15218ae0edb3f97af2b0f611efe007d34f5bc');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1412, 30833, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1413, 30834, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1414, 31823, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', '', 'DDInter', 0, X'789c4d8ed10dc2300c4457b909988515dcc4552c52bbc40e85ed71111ffdb34e7eefee4e21ace1f066b3572c8c62539d3b5784815e26153e170fd210ea78cef348ca612ba8176bd6219adcb688a6cf148744432291f9c655ca2f769056942e2a4548afa574d0e053188d53560693e78221fec06a038d770a0b7b27199fb32e1f9db1fff7dfbefa2e4bc6', NULL, X'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');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1415, 1088, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1416, 1089, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1417, 1090, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1418, 1094, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1419, 1095, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1420, 1097, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1421, 1678, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1422, 4008, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1423, 4009, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1424, 4735, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1425, 7349, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1426, 7350, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1427, 7352, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1428, 7355, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1429, 7359, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1430, 7372, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'789c5592518edb300c44afc203045bb4e825fab71fbd0023d1091b9b3448c959dfbec3748ba21f066468381c3eea9d878a8da490267aa8dd68dc25783fe9a9e34e3c3c0ece019951de7dae9d56dd74944c839a5bce6d1fea46bed00d95b2c4c4fdafa94d683899d3e681e39d8dbea27a48d08eaff3f946f4fe37c1a7fb5588fba129bd8af770b8af27f2ed1e83d84e9a261ffbca6a906c33db2ab4e3ef4243ac4b986492073d851f75bee03686b6b972c04817e2d6e0caa630b89eb4c82171a18de199e86efd8b57ba7860bc15d13bcd403784fdf9c9e65fd6ae0906a0332183770b2956420f35869b268ce3211dad65958347e9acf0115f530c90002e47884d9f49f221d12a0732c06f3b7de7713fcbc86b35cfbacb99bbb4b2aaa4ca37730043c01f067a5d6b1f35f7ff6845cb002897002f5ac0f69563e62b83f3a06b60492040650f8d034c4de5d66620e278891b9bf978adea70edd22fb5ab1480c67c7f66eb9b9a622c7ebd8da19b64c1468f55f0a0e85b957c27248b7cfb0d634aee2c', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1431, 7397, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1432, 7398, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1433, 7399, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1434, 11556, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1435, 13234, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1436, 13512, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1437, 14227, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1438, 14228, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1439, 14563, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1440, 14570, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1441, 15442, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1442, 16266, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1443, 18869, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1444, 21870, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1445, 21882, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1446, 21884, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1447, 21885, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'789c5592518edb300c44afc203045bb4e825fab71fbd0023d1091b9b3448c959dfbec3748ba21f066468381c3eea9d878a8da490267aa8dd68dc25783fe9a9e34e3c3c0ece019951de7dae9d56dd74944c839a5bce6d1fea46bed00d95b2c4c4fdafa94d683899d3e681e39d8dbea27a48d08eaff3f946f4fe37c1a7fb5588fba129bd8af770b8af27f2ed1e83d84e9a261ffbca6a906c33db2ab4e3ef4243ac4b986492073d851f75bee03686b6b972c04817e2d6e0caa630b89eb4c82171a18de199e86efd8b57ba7860bc15d13bcd403784fdf9c9e65fd6ae0906a0332183770b2956420f35869b268ce3211dad65958347e9acf0115f530c90002e47884d9f49f221d12a0732c06f3b7de7713fcbc86b35cfbacb99bbb4b2aaa4ca37730043c01f067a5d6b1f35f7ff6845cb002897002f5ac0f69563e62b83f3a06b60492040650f8d034c4de5d66620e278891b9bf978adea70edd22fb5ab1480c67c7f66eb9b9a622c7ebd8da19b64c1468f55f0a0e85b957c27248b7cfb0d634aee2c', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1448, 21887, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1449, 21889, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1450, 21890, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1451, 21891, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1452, 21893, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1453, 21894, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1454, 21905, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1455, 21906, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1456, 21907, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1457, 21915, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1458, 21916, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1459, 21935, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, reference_text, source, created_at, management_text_blob, mechanism_text_blob, interaction_blob) VALUES (1460, 21936, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', '', 'DDInter', 0, X'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', NULL, X'789c458fc10dc2400c045bd90682908002100df0e0c3d3b9388951ee7c3a3b20bac744487c5733def54569c852c4bc918b16bcc4674c8d2a8f6d15c76395c4c8f48694d4988ce133a32e649990b4242e3fd7a023c8b53dc93c92b2036e5fb66955e30199d34cd1952116e766e965eb0ced72bf1e4f7b1ccec72ef320e4818fd2ccbb4a66613af5ba6c6ad9064cabe345cb82fe8dc4cd29f2a4b9ea5a068b4ab6d8f585ffbfec3e281b57bb');